Document Detail


Accumulation of membrane-bound melanosomes occurs in Langerhans cells of patients with the Leopard syndrome.
MedLine Citation:
PMID:  1424250     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Langerhans cells in the lentigines of four patients with the Leopard syndrome contained large membrane bound accumulations of melanin granules. Giant melanosomes were only seen in two patients. The patients had no immune-based symptoms relating to their lentigines. The Leopard Syndrome, also known as multiple lentigines syndrome, progressive cardiomyopathic lentiginosis, lentiginosis profusa syndrome and the cardiocutaneous syndrome, refers to an inherited abnormality of the skin, often associated with cardiomyopathy. The aetiology of the condition is so far unknown and the penetrance is variable. Here we describe electron microscopical findings of large accumulations of melanin within Langerhans cells.
Authors:
P R Fryer; F M Pope
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental dermatology     Volume:  17     ISSN:  0307-6938     ISO Abbreviation:  Clin. Exp. Dermatol.     Publication Date:  1992 Jan 
Date Detail:
Created Date:  1992-12-07     Completed Date:  1992-12-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7606847     Medline TA:  Clin Exp Dermatol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  13-5     Citation Subset:  IM    
Affiliation:
Electron Microscopy, Clinical Research Centre, Harrow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiomyopathies / pathology
Female
Humans
Langerhans Cells / ultrastructure*
Lentigo / pathology*
Male
Melanocytes / ultrastructure*
Microscopy, Electron
Syndrome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical, cytogenetic and molecular investigations in three patients with Wolf-Hirschhorn syndrome.
Next Document:  How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis.